Adaptimmune Therapeutics Plc (ADAP)

Trade ADAP now with
11/16/2019 9:28:12 AM Adaptimmune Says Updated Data From Phase 1 ADP-A2M4 Trial Demonstrating Continued Clinical Benefit For Synovial Sarcoma
10/9/2019 8:23:13 AM Adaptimmune And Cryoport Announce Deal To Ensure Safe And Fully Monitored Transport Of Adaptimmune’s Cell Therapies
9/9/2019 8:12:25 AM Adaptimmune Says FDA Granted ODD To SPEAR T-cells Targeting MAGE-A4
7/18/2019 8:06:06 AM Adaptimmune Starts SURPASS Clinical Trial With First Next-Generation SPEAR T-cells Targeting MAGE-A4
1/7/2019 7:41:13 AM Adaptimmune: SRC Endorses Dose Escalation In AFP Study In Patients With Hepatocellular Carcinoma To Second Dose Cohort
11/6/2018 7:38:46 AM Adaptimmune Q3 Revenue $40.8 Mln Vs $27.2 Mln Last Year
10/20/2018 12:37:08 PM Adaptimmune Presents Initial Data From First Two Cohorts Of Ongoing Studies With Its MAGE-A10 And MAGE-A4 SPEAR T-cells
9/7/2018 1:45:56 PM Adaptimmune Therapeutics Closes Registered Direct Offering Of American Depositary Shares
8/2/2018 7:37:57 AM Adaptimmune Therapeutics Q2 Loss/shr Widens To $0.08 From $0.04 Last Year
7/24/2018 7:34:13 AM GSK And Adaptimmune Complete Transition Of NY-ESO SPEAR T-cell Therapy Program To GSK
6/11/2018 7:33:19 AM Adaptimmune Says Data From Pilot Study Of NY-ESO SPEAR T-cells In Synovial Sarcoma Will Be Published In Cancer Discovery
6/4/2018 7:33:08 AM Adaptimmune Presents Detailed Safety Update From Ongoing MAGE-A10 Pilot Studies At ASCO
6/4/2018 7:31:57 AM Adaptimmune: Independent Safety Review Committee Recommended Dose Escalation In MAGE-A4 Basket Study
6/2/2018 11:40:48 AM Adaptimmune Therapeutics Presents Initial Data From Ongoing Pilot Study Of NY-ESO SPEAR T-cells In MRCLS
5/9/2018 7:34:33 AM Adaptimmune Q1 Net Loss Attributable To Holders $21.1 Mln Or $0.04/Shr Vs Loss $21.8 Mln Or $0.05/Shr Last Year
4/12/2018 8:01:29 AM Adaptimmune Therapeutics Names John Furey Independent Non-Executive Director; Peter Thompson Stepping Down From Board